Skip to content
NORTHSTAR CRYO

Science and progress

What the data show so far.

Key results from the founding team's published and preprint research, with labels showing what has completed peer review.

Key results

  • Preprint

    Viability and recovery

    Viability after vitrification and rewarming was 93.6 ± 2.2% for human islets and 92.7 ± 2.2% for human stem cell-derived islets. Recovery was 92.9 ± 1.4% and 93.5 ± 3.3%, respectively.

    Source: bioRxiv, 2026, Fig. 3B.

  • Preprint

    Function

    Function was confirmed in vitro and in vivo.

  • Preprint; 2-year data unpublished

    Long-term storage

    Human islets stored for up to one year restored normoglycemia in diabetic mice. Storage of up to two years has been demonstrated in unpublished data.

  • Published and unpublished

    Species and islet types

    Demonstrated with human islets and human stem cell-derived islets, as well as porcine and mouse islets; non-human primate islets in unpublished studies.

Results from a preprint that has not yet completed peer review. Preprint: Rao JS, Guo Z, Khashim Z, et al.; Etheridge ML, Bischof JC, Finger EB, Clinical-grade cryopreservation unlocks transplant-ready human pancreatic and stem cell-derived islets for diabetes therapy.

Publications

Selected publications.

Video

NorthStar Cryo in one minute.

Collaborate

Partner with us

We work with developers of islet and cell-based therapies to evaluate CryoMesh in their programs. Major pharmaceutical companies are evaluating CryoMesh.